An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated with Opioids Chronically

First published 04/03/2016

Last updated 02/07/2024

EU PAS number:

EUPAS12669

Study

Finalised

Documents

Study protocol

Initial protocol

D3820R00009 CSP - PRAC 07312015 final

English (418.76 KB - PDF) View document

Updated protocol

m1-8-2 D3820R00009 PASS CSP_v6.1_29Mar2021

First published: 22/02/2024

English (1.25 MB - PDF) View document

Study results

Naloxegol_SES_final report_2022_V1.0_Abstract

English (595.05 KB - PDF) View document

Study report

Other information

Secondary tabs